


Global pharmaceutical industry initiatives and plans to contain AMR



Steve Brooks
Manufacturing Lead AMR Industry Alliance

World Antimicrobial Awareness Week 2021 | Rethinking the AMR agenda. Nov 24 2021

AMR Industry Alliance



Formed in 2017, the Alliance represents over 100 diagnostics, biotechs, generics, and R&D pharmaceutical companies

Through collective efforts, the Alliance harnesses, measures and drives the power of the life science industry to curb AMR in four main pillars:



manufacturing

To mitigate environmental impact and advance responsible manufacturing through standard setting



access

To ensure existing and new quality antibiotics are available to all, and improve and accelerate access to diagnostics, including in low- and middle-income countries



appropriate use

Of antibiotics to reduce the spread of AMR with the support of vaccines and diagnostics




research & science

To meet public health needs with new innovative diagnostics and treatments

Manufacturing - one source of antibiotics in the Environment

MANUFACTURING
One Potential
Source of Many



Boxall (2004)


AMR Industry Alliance accomplishments and objectives



Published two prior reports and 3rd report (2021) drafted with executive summary published, tracking progress to our commitments

Developed our Common Antibiotic Manufacturing Framework (CAMF) & Predicted No-Effect Concentration (PNEC) Targets for antibiotic discharge.

Sponsoring development of BSI Publicly Available Specification and plans to develop a certification scheme to provide stakeholder assurance that antibiotics are made responsibly.



2021 PROGRESS REPORT

EXECUTIVE SUMMARY



Integrated Environmental Assessment and Management

Brief Communication | Open Access | CC | i

Science-based Targets for Antibiotics in Receiving Waters from Pharmaceutical Manufacturing Operations

Joan Tell , Daniel J Caldwell, Andreas Häner, Jutta Hellstern, Birgit Hoeger, Romain Journeil, Frank Mastrocco, Jim J Ryan, Jason Snape, Jürg Oliver Straub, Jessica Vestel,

First published: 18 March 2019 | <https://doi.org/10.1002/ieam.4141> | Citations: 31

Alliance 2021 Executive Summary Report: <https://www.amrindustryalliance.org/progress-report/>
Alliance 2020 Progress report: <https://www.amrindustryalliance.org/wp-content/uploads/2020/01/AMR-2020-Progress-Report.pdf>
Alliance Framework: https://www.amrindustryalliance.org/wp-content/uploads/2019/11/Making-antibiotics-responsibly_A-common-manufacturing-framework-to-tackle-AMR.pdf
PNECS Science-based Targets for Antibiotics in Receiving Waters from Pharmaceutical Manufacturing Operations - Tell - 2019 - Integrated Environmental Assessment and Management - Wiley Online Library

Manufacturing and the Environment Highlights; Key insights on Progress*



- **Majority of Alliance members' manufacturing sites have been assessed against the CAMF and meet these requirements:**
 - 76% meet requirements fully, 98% either fully or partially
 - 87% products manufactured at sites owned by Alliance members met PNEC targets.
- **Direct suppliers have also worked to implement Alliance requirements related to appropriate manufacturing.**
 - Alliance expectations have been conveyed to 86% of suppliers.
 - Overall, 44% of supplier sites have been assessed against the Framework; 50% of assessed sites meet these requirements fully and 63% meet the requirements fully or partially;
 - 42% of products made at supplier sites been assessed against PNEC, with 73% of these meeting these targets.

Alliance Manufacturing Members

R&D and generic biopharmaceutical companies

